Pain medicine case reports · 2026
Microfragmented Adipose Tissue (MFAT) Injection for Refractory Generator Pocket Pain (GPP) in Spinal Cord Stimulation (SCS): A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vendramin Patrizia, Martini Alvise, Bonora Eleonora, Tomasi Michael, Pozzobon Nicola, Polati Luca, Gottin Leonardo, Parolini Massimo, Polati Enrico, Schweiger Vittorio
Аннотация
BACKGROUND: Generator pocket pain (GPP) may develop in spinal cord stimulation (SCS) patients, with a frequency ranging from 0.9% to 64%. While several treatments have been proposed, the only available options for SCS patients experiencing refractory pain are implantable pulse generator (IPG) relocation or removal.
CASE REPORT: We treated a 62-year-old man with late-onset refractory GPP using the autologous microfragmented adipose tissue (MFAT) injection into the IPG pocket. A total of 30 mL of MFAT harvested from abdominal fat was injected. The procedure was well tolerated, with no adverse events. The patient reported a significant reduction in pain intensity immediately after the injection, with his visual analog scale (VAS) score decreasing from 80 to 20/100. At the third-month follow-up, he continued to experience the same level of pain relief.
CONCLUSION: The autologous MFAT injection in refractory GPP patients is a promising salvage option. However, additional cases will be needed to better evaluate the efficacy and long-term outcomes of this treatment.
CASE REPORT: We treated a 62-year-old man with late-onset refractory GPP using the autologous microfragmented adipose tissue (MFAT) injection into the IPG pocket. A total of 30 mL of MFAT harvested from abdominal fat was injected. The procedure was well tolerated, with no adverse events. The patient reported a significant reduction in pain intensity immediately after the injection, with his visual analog scale (VAS) score decreasing from 80 to 20/100. At the third-month follow-up, he continued to experience the same level of pain relief.
CONCLUSION: The autologous MFAT injection in refractory GPP patients is a promising salvage option. However, additional cases will be needed to better evaluate the efficacy and long-term outcomes of this treatment.